Novo kidney trial finds Ozempic cuts cardiac risks in diabetics

Novo Nordisk's widely used diabetes drug Ozempic delayed progression of chronic kidney disease in diabetes patients, a large late-stage study found, cutting the risk of major cardiac events and death by 24%.